Trial to evaluate the efficacy of Dupilumab in | Clinical Research Studies Listing

Trial to evaluate the efficacy of Dupilumab in Eosinophilic Gastritis

Recruiting

12 years - 70 years

All

Phase 2

5 participants needed

1 Location

Brief description of study

To assess the efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to reduce eosinophilic inflammation in the stomach of participants with eosinophilic gastritis (EG)/ eosinophilic gastroenteritis (EGE).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Eosinophilic Gastritis,Eosinophilic Gastroenteritis
Age: 12 years - 70 years
Gender: All

Male or Female, Histologically active Eosinophilic Gastri, Age 12-70

Updated on 04 Aug 2024. Study ID: 844860

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Trial to evaluate the efficacy of Dupilumab in Eosinophilic Gastritis

Brief description of study

Eligibility of study

Find a site

Interested in the study